-5%
Abemaciclib is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. These kinases, when activated by cyclin D, play a key role in regulating cell cycle progression. In estrogen receptor–positive breast cancer cells, CDK4/6-mediated phosphorylation of the retinoblastoma (Rb) protein promotes transition from the G1 to the S phase, leading to tumor cell proliferation. By inhibiting CDK4/6, abemaciclib suppresses cell cycle progression and tumor growth.
Abeclib 150 mg Tablet is indicated for the treatment of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced or metastatic breast cancer in adults.
May be taken with or without food
Patients should be advised to take the medication at approximately the same time each day to maintain consistent drug levels